| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/IJCP.12906 |
| P698 | PubMed publication ID | 28032429 |
| P50 | author | Clifford J Bailey | Q37842217 |
| P2093 | author name string | Clifford J Bailey | |
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002 | Q28196337 | ||
| Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk | Q46758929 | ||
| Achievement of goals in U.S. diabetes care, 1999-2010. | Q51045064 | ||
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
| American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. | Q30578967 | ||
| Factors associated with clinical inertia: an integrative review | Q33639428 | ||
| The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic | Q34382980 | ||
| Clinical inertia | Q34428121 | ||
| The Translating Research Into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care | Q34508843 | ||
| Diabetes performance measures: current status and future directions | Q35060223 | ||
| A systematic review of adherence with medications for diabetes | Q35757475 | ||
| Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin | Q35831626 | ||
| The impact of treatment noncompliance on mortality in people with type 2 diabetes | Q35976392 | ||
| Making performance indicators work: experiences of US Veterans Health Administration | Q36128990 | ||
| Multidrug treatment of type 2 diabetes: a challenge for compliance | Q36783845 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Sustained hyperglycemia among patients with diabetes: what matters when action is needed? | Q37269423 | ||
| Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people | Q37278100 | ||
| Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes | Q37577162 | ||
| Controversies in the cardiovascular management of type 2 diabetes | Q37812197 | ||
| Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials | Q37866586 | ||
| Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 | ||
| Is glycemic control improving in U.S. adults? | Q40164421 | ||
| Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events | Q40431693 | ||
| Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes | Q40873421 | ||
| Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials | Q42326639 | ||
| Improving the management of chronic disease at community health centers | Q43617545 | ||
| The association between quality of care and the intensity of diabetes disease management programs | Q43840289 | ||
| Evaluation of risk factors for development of complications in Type II diabetes in Europe | Q44075872 | ||
| Setting performance targets in pay for performance programmes: what can we learn from QOF? | Q44480449 | ||
| Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study | Q44686996 | ||
| Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? | Q45285707 | ||
| Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 | ||
| P433 | issue | 12 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 988-995 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia | |
| P478 | volume | 70 |
| Q92383338 | A comparison of clinical pharmacist management of type 2 diabetes versus usual care in a federally qualified health center |
| Q55505539 | Adherence to self-care practices, glycemic status and influencing factors in diabetes patients in a tertiary care hospital in Delhi. |
| Q55235345 | Antidiabetic medication and quality of life: A comment on Chaturvedi et al. (2018). |
| Q88967638 | Author's reply |
| Q92301581 | Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective Study |
| Q58596775 | Clinical inertia on insulin treatment intensification in type 2 diabetes mellitus patients of a tertiary public diabetes center with limited pharmacologic armamentarium from an upper-middle income country |
| Q53192248 | Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity. |
| Q88447763 | Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately |
| Q89685776 | Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial |
Search more.